questions. morning, good Annabel and Glenn you, three very Thank important Yes.
to labeling you it's point premature the had any know, with at FDA. as discussions Regarding this have Annabel, labeling,
not any I I mentioned have that to make want So discussions. we sure labeling entered
we broad expectations that monthly Our -- have hope and that that is are injections. that consistent a label with is will -- require
me one individually. of Let take each them
As were which we of majority with the XXX phobia, is within the clinical within vast yet, the microns the presented center and have what in to is done have point. GATHERX several really that of as we meetings. not seen GATHERX this as patients We've in defined
fact, patients that X In but literally eligible. to micron their on center patients their from cetera. would little there's in point bump patients a stoves, many point, photoreceptor hands practice who There may navigate, were X cells not away clinical are if center involved, micron, be the those into island have allows et paraphovial fixation burn and chairs, them not be
we to we So effective denied access of a X those for patients believe be and that label safe because micron. broad that eligible a be wouldn't and would drug
Now is we as want application as monthly concerned, far monthly to our injections label. have on
know, don't label. to treat you colleagues according my the really As
treat is anti-VEGF us there that experience, a most has the instance, on label. with anti-VEGF of this from the see regimen. treatment for no can You extend extend And treatment
the is there purposes. reimbursement for label So really
that So reimbursed. label have usage less to would that maximum makes the you want would logically, still be sense on so any the it
any formal our broad And into label a a entered we again, that the with have that want again, not is have I says expectation say to monthly labeling discussions FDA. So that we'll application.
topic important as all. that of good terms at measure don't a in As question we second very of there, is which function is your Annabel, a identified have concerned, really far function you've
there that? experience no has for this is glaucoma been done, we measure an minimum end. have of changes, earlier, and may function the at contrast light a visual the entirely discussed dimension. see as the we sensitivity they tunnel as with to At with forth. are expand consists is end duty test visual fact, color great vision function. bright of really This like going a pops of tests we rarely changes, In instance, so or things good into an Are -- day, new the acuity in So not to opportunity patient dark
And we experience. in the of are terms patient investing heavily expanding
life not For will I be acuity out now, -- visual there lots may but patients patients on not functional to a difficult work tell can work a know sentence, what it'd changes. because reading side you and are have will life. couldn't anybody imagine is your a the there finish you if normal have normal And you and XXXX, can of spot to be live you able who very that vision visual the to able a function for of had of be a
very such of regardless is diabetes, the going favorable a need back AMD diseases This acuity degeneration intermediate that results, as the desperate visual may FDA. is visual all There's the are to as in the with regards complement visual in had help. Glenn time AMD, happens patients allow the be which instance, patients we've other question deficit, by activation. up of intermediate acuity In where deficit, will XXXX, signs visual are So because in. come there fact function said, plans as function discussions for well, our such but forward? molecular your to of As to I think driven was what
said Zimura. this safe X see. to investing for of Back opening in the we where that the with just this functional regarding of I up which that one treatment is of new greatly the benefit back we color is generation changes that I patients, The what minimal... from as have degeneration. is the Zimura say would believe, time We're opportunities heavily is, Glenn. I with in thing large... And macular III the Intermediate effective you, with range. serious a a would here is blindness et believe very that potentially cetera. in This cause the have X. patients in can fluid broad have version is last experience drug that those remember, first delivery vision, beginning intermediate have what even There sustained are degeneration go And version and patients X I version again, with X, to results. benefits positive country. of macular intermediate we And a macular is very largest door that Phase
